Literature DB >> 11389700

Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886.

J P Kehrer1, S S Biswal, E La, P Thuillier, K Datta, S M Fischer, J P Vanden Heuvel.   

Abstract

Although MK886 was originally identified as an inhibitor of 5-lipoxygenase activating protein (FLAP), recent data demonstrate that this activity does not underlie its ability to induce apoptosis [Datta, Biswal and Kehrer (1999) Biochem. J. 340, 371--375]. Since FLAP is a fatty-acid binding protein, it is conceivable that MK886 may affect other such proteins. A family of nuclear receptors that are activated by fatty acids and their metabolites, the peroxisome-proliferator-activated receptors (PPARs), have been implicated in apoptosis and may represent a target for MK886. The ability of MK886 to inhibit PPAR-alpha, -beta and -gamma activity was assessed using reporter assay systems (peroxisome-proliferator response element--luciferase). Using a transient transfection system in monkey kidney fibroblast CV-1 cells, mouse keratinocyte 308 cells and human lung adenocarcinoma A549 cells, 10--20 microM MK886 inhibited Wy14,643 activation of PPAR alpha by approximately 80%. Similar inhibition of PPAR alpha by MK886 was observed with a stable transfection reporter system in CV-1 cells. Only minimal inhibitory effects were seen on PPAR beta and PPAR gamma. MK886 inhibited PPAR alpha by a non-competitive mechanism as shown by its effects on the binding of arachidonic acid to PPAR alpha protein, and a dose-response study using a transient transfection reporter assay in COS-1 cells. An assay assessing PPAR ligand-receptor interactions showed that MK886 prevents the conformational change necessary for active-complex formation. The expression of keratin-1, a protein encoded by a PPAR alpha-responsive gene, was reduced by MK886 in a culture of mouse primary keratinocytes, suggesting that PPAR inhibition has functional consequences in normal cells. Although Jurkat cells express all PPAR isoforms, various PPAR alpha and PPAR gamma agonists were unable to prevent MK886-induced apoptosis. This is consistent with MK886 functioning as a non-competitive inhibitor of PPAR alpha, but may also indicate that PPAR alpha is not directly involved in MK886-induced apoptosis. Although numerous PPAR activators have been identified, the results show that MK886 can inhibit PPAR alpha, making it the first compound identified to have such an effect.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389700      PMCID: PMC1221919          DOI: 10.1042/0264-6021:3560899

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  46 in total

1.  Properties of carcinogen altered mouse epidermal cells resistant to calcium-induced terminal differentiation.

Authors:  M Kulesz-Martin; A E Kilkenny; K A Holbrook; V Digernes; S H Yuspa
Journal:  Carcinogenesis       Date:  1983-11       Impact factor: 4.944

2.  PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs.

Authors:  T C He; T A Chan; B Vogelstein; K W Kinzler
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

3.  Evidence for peroxisome proliferator-activated receptor (PPAR)alpha-independent peroxisome proliferation: effects of PPARgamma/delta-specific agonists in PPARalpha-null mice.

Authors:  J G DeLuca; T W Doebber; L J Kelly; R K Kemp; S Molon-Noblot; S P Sahoo; J Ventre; M S Wu; J M Peters; F J Gonzalez; D E Moller
Journal:  Mol Pharmacol       Date:  2000-09       Impact factor: 4.436

4.  Peroxisome proliferators induce apoptosis and decrease DNA synthesis in hepatoma cell lines.

Authors:  V Goll; C Viollon-Abadie; L Nicod; L Richert
Journal:  Hum Exp Toxicol       Date:  2000-03       Impact factor: 2.903

5.  Suppression of mouse hepatocyte apoptosis by peroxisome proliferators: role of PPARalpha and TNFalpha.

Authors:  S C Hasmall; N H James; N Macdonald; F J Gonzalez; J M Peters; R A Roberts
Journal:  Mutat Res       Date:  2000-03-17       Impact factor: 2.433

6.  Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis.

Authors:  Y Tsubouchi; H Sano; Y Kawahito; S Mukai; R Yamada; M Kohno; K Inoue; T Hla; M Kondo
Journal:  Biochem Biophys Res Commun       Date:  2000-04-13       Impact factor: 3.575

7.  Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis.

Authors:  N Chattopadhyay; D P Singh; O Heese; M M Godbole; T Sinohara; P M Black; E M Brown
Journal:  J Neurosci Res       Date:  2000-07-01       Impact factor: 4.164

8.  Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis.

Authors:  D G Tang; Y Q Chen; K V Honn
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

9.  In vivo behavior of murine epidermal cell lines derived from initiated and noninitiated skin.

Authors:  C J Conti; J W Fries; A Viaje; D R Miller; R Morris; T J Slaga
Journal:  Cancer Res       Date:  1988-01-15       Impact factor: 12.701

10.  Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors.

Authors:  S A Kliewer; K Umesono; D J Noonan; R A Heyman; R M Evans
Journal:  Nature       Date:  1992-08-27       Impact factor: 49.962

View more
  45 in total

1.  AMPK enhances the expression of pancreatic duodenal homeobox-1 via PPARalpha, but not PPARgamma, in rat insulinoma cell line INS-1.

Authors:  Hua Guo; Shui Sun; Xu Zhang; Xiu-juan Zhang; Ling Gao; Jia-jun Zhao
Journal:  Acta Pharmacol Sin       Date:  2010-07-19       Impact factor: 6.150

2.  MK886 inhibits the pioglitazone-induced anti-invasion of MDA-MB-231 cells is associated with PPARα/γ, FGF4 and 5LOX.

Authors:  Kalpanah Nadarajan; Prabha Balaram; Boon Yin Khoo
Journal:  Cytotechnology       Date:  2016-01-11       Impact factor: 2.058

3.  Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area: involvement of PPAR-alpha nuclear receptors.

Authors:  Antonio Luchicchi; Salvatore Lecca; Stefano Carta; Giuliano Pillolla; Anna L Muntoni; Sevil Yasar; Steven R Goldberg; Marco Pistis
Journal:  Addict Biol       Date:  2010-05-11       Impact factor: 4.280

4.  Fenofibrate subcellular distribution as a rationale for the intracranial delivery through biodegradable carrier.

Authors:  M Grabacka; P Waligorski; A Zapata; D A Blake; D Wyczechowska; A Wilk; M Rutkowska; H Vashistha; R Ayyala; T Ponnusamy; V T John; F Culicchia; A Wisniewska-Becker; K Reiss
Journal:  J Physiol Pharmacol       Date:  2015-04       Impact factor: 3.011

5.  Interference with acute nausea and anticipatory nausea in rats by fatty acid amide hydrolase (FAAH) inhibition through a PPARα and CB1 receptor mechanism, respectively: a double dissociation.

Authors:  Erin M Rock; Cheryl L Limebeer; Jordan M Ward; Arianne Cohen; Katherine Grove; Micah J Niphakis; Benjamin F Cravatt; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2015-08-23       Impact factor: 4.530

6.  Interactions of PPAR-alpha and adenosine receptors in hypoxia-induced angiogenesis.

Authors:  Yasmeen Q Rizvi; Chander S Mehta; Adebayo Oyekan
Journal:  Vascul Pharmacol       Date:  2013-09-17       Impact factor: 5.773

7.  Uncoupling protein-2 up-regulation and enhanced cyanide toxicity are mediated by PPARalpha activation and oxidative stress.

Authors:  X Zhang; L Li; K Prabhakaran; L Zhang; H B Leavesley; J L Borowitz; G E Isom
Journal:  Toxicol Appl Pharmacol       Date:  2007-05-18       Impact factor: 4.219

8.  Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors.

Authors:  Carmen Mazzola; Julie Medalie; Maria Scherma; Leigh V Panlilio; Marcello Solinas; Gianluigi Tanda; Filippo Drago; Jean Lud Cadet; Steven R Goldberg; Sevil Yasar
Journal:  Learn Mem       Date:  2009-04-29       Impact factor: 2.460

9.  Combination Therapy of PPARgamma Ligands and Inhibitors of Arachidonic Acid in Lung Cancer.

Authors:  Jordi Tauler; James L Mulshine
Journal:  PPAR Res       Date:  2009-03-04       Impact factor: 4.964

10.  Modulation peroxisome proliferators activated receptor alpha (PPAR alpha) and acyl coenzyme A: cholesterol acyltransferase1 (ACAT1) gene expression by fatty acids in foam cell.

Authors:  Javad Zavvar Reza; Mahmoud Doosti; Masoud Salehipour; Malehieh Packnejad; Majed Mojarrad; Mansour Heidari
Journal:  Lipids Health Dis       Date:  2009-09-02       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.